ScholarIQanswers from OpenAlex & ORCID
Yi‐Long Wu
ResearcherPublications, citations & collaboration network
Yi‐Long Wu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yi‐Long Wu have?
ScholarIQindexed works
Yi‐Long Wu has 2,203 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yi‐Long Wu have?
ScholarIQcitation count
Yi‐Long Wu has 113,278 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yi‐Long Wu?
ScholarIQh-index
Yi‐Long Wu has an h-index of 134 in OpenAlex.
What is the i10-index of Yi‐Long Wu?
ScholarIQi10-index
Yi‐Long Wu has an i10-index of 661 in OpenAlex.
What is the ORCID of Yi‐Long Wu?
ScholarIQorcid
The ORCID for Yi‐Long Wu is on the source record.
What is the OpenAlex record for Yi‐Long Wu?
ScholarIQopenalex
The OpenAlex for Yi‐Long Wu is on the source record.
What are the most-cited papers on Yi‐Long Wu?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw, Kari Chansky, John Crowley, Ramón Rami–Porta, Hisao Asamura, Wilfried Eberhardt, Andrew G. Nicholson, Patti A. Groome, Alan Mitchell, Vanessa Bolejack, Peter Goldstraw, Ramón Rami–Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy J. Giroux, Fergus Gleeson, Patti A. Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Antoon Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan P. van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna K. Nowak, Michael Peake, Thomas W. Rice, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Nagahiro Saijo, Paul Van Schil, Jean‐Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William D. Travis, Ming‐Sound Tsao, Andrew T. Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp H. Kernstine, Hedy L. Kindler, Lee M. Krug, Kristiaan Nackaerts, Harvey I. Pass, David C. Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene H. Blackstone, F. Abad Cavaco, Emilio Ansótegui Barrera, J. Abal Arca, Isaura Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, David Ball, G.K. Bascom, Ana Isabel Blanco Orozco, M.A. González Castro, Matthew G. Blum, Domingo Chimondeguy, Vlado Cvijanović, Sebastián Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, Felipe Andreo García, Kwun M. Fong, Gloria Francisco Corral
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares